🇺🇸 FDA
Pipeline program

Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)

20190135

Phase 1 other active

Quick answer

Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101) for Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Phase
Phase 1
Modality
other
Status
active

Clinical trials